JP2008510126A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008510126A5 JP2008510126A5 JP2007506605A JP2007506605A JP2008510126A5 JP 2008510126 A5 JP2008510126 A5 JP 2008510126A5 JP 2007506605 A JP2007506605 A JP 2007506605A JP 2007506605 A JP2007506605 A JP 2007506605A JP 2008510126 A5 JP2008510126 A5 JP 2008510126A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- rhoa
- anln
- detecting
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100033393 Anillin Human genes 0.000 claims description 20
- 101000732632 Homo sapiens Anillin Proteins 0.000 claims description 20
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 7
- 229920001184 polypeptide Polymers 0.000 claims 25
- 102000004196 processed proteins & peptides Human genes 0.000 claims 25
- 108090000765 processed proteins & peptides Proteins 0.000 claims 25
- 101100356682 Caenorhabditis elegans rho-1 gene Proteins 0.000 claims 20
- 101150111584 RHOA gene Proteins 0.000 claims 20
- 238000000034 method Methods 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 11
- 210000004027 cell Anatomy 0.000 claims 7
- 230000003993 interaction Effects 0.000 claims 6
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 5
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 5
- 108010085238 Actins Proteins 0.000 claims 4
- 102000007469 Actins Human genes 0.000 claims 4
- 230000012292 cell migration Effects 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 238000012216 screening Methods 0.000 claims 4
- 230000004899 motility Effects 0.000 claims 3
- 238000004393 prognosis Methods 0.000 claims 3
- 230000006820 DNA synthesis Effects 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 230000021164 cell adhesion Effects 0.000 claims 2
- 230000022131 cell cycle Effects 0.000 claims 2
- 230000004709 cell invasion Effects 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- 239000012636 effector Substances 0.000 claims 2
- 230000004807 localization Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000013508 migration Methods 0.000 claims 2
- 231100000590 oncogenic Toxicity 0.000 claims 2
- 230000002246 oncogenic effect Effects 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 210000003518 stress fiber Anatomy 0.000 claims 2
- 230000007704 transition Effects 0.000 claims 2
- 230000009087 cell motility Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000014509 gene expression Effects 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 238000010837 poor prognosis Methods 0.000 claims 1
- 230000008569 process Effects 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 238000010186 staining Methods 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60056104P | 2004-08-10 | 2004-08-10 | |
| US60/600,561 | 2004-08-10 | ||
| PCT/JP2005/014887 WO2006016697A1 (en) | 2004-08-10 | 2005-08-09 | Non-small cell lung cancer-related gene, anln, and its interactions with rhoa |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008510126A JP2008510126A (ja) | 2008-04-03 |
| JP2008510126A5 true JP2008510126A5 (cg-RX-API-DMAC7.html) | 2008-09-25 |
| JP4874234B2 JP4874234B2 (ja) | 2012-02-15 |
Family
ID=35355888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007506605A Expired - Fee Related JP4874234B2 (ja) | 2004-08-10 | 2005-08-09 | 非小細胞肺癌関連遺伝子ＡＮＬＮ、およびそのＲｈｏＡとの相互作用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20090297500A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1787122B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP4874234B2 (cg-RX-API-DMAC7.html) |
| AT (1) | ATE483979T1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE602005024021D1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2006016697A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8131476B2 (en) | 2006-08-07 | 2012-03-06 | General Electric Company | System and method for co-registering multi-channel images of a tissue micro array |
| US8060348B2 (en) | 2006-08-07 | 2011-11-15 | General Electric Company | Systems for analyzing tissue samples |
| AU2007322206A1 (en) * | 2006-11-13 | 2008-05-29 | Source Precision Medicine, Inc. | Gene expression profiling for identification, monitoring, and treatment of lung cancer |
| EP2142648A4 (en) * | 2007-03-30 | 2011-09-14 | Oncotherapy Science Inc | SCREENING AND ANTI-NSCLC THERAPEUTIC METHOD TARGETING THE CDCA8-AURKB COMPLEX |
| EP2161577A1 (en) * | 2008-09-01 | 2010-03-10 | Atlas Antibodies AB | ANLN protein |
| US20120041274A1 (en) | 2010-01-07 | 2012-02-16 | Myriad Genetics, Incorporated | Cancer biomarkers |
| US9125899B1 (en) | 2010-06-17 | 2015-09-08 | Stc.Unm | Modulators of GTPases and their use |
| EP3812469A1 (en) | 2010-07-07 | 2021-04-28 | Myriad Genetics, Inc. | Gene signatures for cancer prognosis |
| SG186953A1 (en) | 2010-07-09 | 2013-02-28 | Somalogic Inc | Lung cancer biomarkers and uses thereof |
| US9605319B2 (en) | 2010-08-30 | 2017-03-28 | Myriad Genetics, Inc. | Gene signatures for cancer diagnosis and prognosis |
| JP6127972B2 (ja) | 2011-09-09 | 2017-05-17 | コニカミノルタ株式会社 | 組織染色方法 |
| ES2674318T3 (es) * | 2011-10-24 | 2018-06-28 | Somalogic, Inc. | Biomarcadores de cáncer de pulmón y usos de los mismos |
| JP5806168B2 (ja) * | 2012-06-19 | 2015-11-10 | 国立大学法人 岡山大学 | 抗浸潤薬の新規スクリーニング法 |
| CA2891653A1 (en) | 2012-11-16 | 2014-05-22 | Myriad Genetics, Inc. | Gene signatures for cancer prognosis |
| EP3143160B1 (en) | 2014-05-13 | 2019-11-06 | Myriad Genetics, Inc. | Gene signatures for cancer prognosis |
| US10870854B2 (en) | 2016-06-09 | 2020-12-22 | The Board Of Regents Of The University Of Texas System | Inhibitory RNA-based therapeutics targeting ANLN for cancer treatment |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200413725A (en) * | 2002-09-30 | 2004-08-01 | Oncotherapy Science Inc | Method for diagnosing non-small cell lung cancers |
| CA2522299A1 (en) * | 2003-04-15 | 2004-10-28 | Avalon Pharmaceuticals, Inc | Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods |
-
2005
- 2005-08-09 WO PCT/JP2005/014887 patent/WO2006016697A1/en not_active Ceased
- 2005-08-09 US US11/573,393 patent/US20090297500A1/en not_active Abandoned
- 2005-08-09 EP EP05770407A patent/EP1787122B1/en not_active Expired - Lifetime
- 2005-08-09 JP JP2007506605A patent/JP4874234B2/ja not_active Expired - Fee Related
- 2005-08-09 DE DE602005024021T patent/DE602005024021D1/de not_active Expired - Lifetime
- 2005-08-09 AT AT05770407T patent/ATE483979T1/de not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008510126A5 (cg-RX-API-DMAC7.html) | ||
| JP5717937B2 (ja) | プロテアソーム阻害療法を用いた患者の同定、判定および治療方法 | |
| US10041126B2 (en) | Monocyte biomarkers for cancer detection | |
| JP2009519002A5 (cg-RX-API-DMAC7.html) | ||
| JP2018536700A (ja) | Ｐａｒｐ阻害剤を用いる小細胞肺がんの治療 | |
| WO2008132155A2 (en) | Inhibitors of the binding between hdm2 and the proteasome | |
| JP2012512389A5 (cg-RX-API-DMAC7.html) | ||
| CN109337909B (zh) | 一种检测肝癌耐药细胞株的核酸适体及其应用 | |
| JP2009507229A (ja) | 生物学的状態の診断及び／又は治療に有用なバイオマーカーを同定するための方法及び組成物 | |
| US12325880B2 (en) | Identification of PDE3 modulator responsive cancers | |
| WO2022010919A2 (en) | Exosomal tumor biomarkers and collections thereof | |
| JP2008502332A5 (cg-RX-API-DMAC7.html) | ||
| JP2007526759A5 (cg-RX-API-DMAC7.html) | ||
| Lan et al. | Significance of the detection of TIM-3 and FOXJ1 in prostate cancer | |
| Murray et al. | Quantitative proteomic profiling of pleomorphic human sarcoma identifies CLIC1 as a dominant pro-oncogenic receptor expressed in diverse sarcoma types | |
| KR20190012715A (ko) | Park7, apex1 및 s1pr1 단백질을 포함하는 혈관질환 진단용 바이오마커 | |
| Hui | Human hepatocellular carcinoma: expression profiles-based molecular interpretations and clinical applications | |
| Shukla et al. | Unbiased peptoid cell screen identifies a peptoid targeting newly appeared cell surface vimentin on tumor transformed early lung cancer cells | |
| CN112162097B (zh) | Gdf1作为评估pd-1单抗治疗效果的生物标志物 | |
| CN104039328B (zh) | 对蛋白酶体抑制剂的反应的生物标记 | |
| CN105203763B (zh) | 一种口腔癌特异性检测的试剂盒 | |
| JP2007523640A5 (cg-RX-API-DMAC7.html) | ||
| Midorikawa et al. | Molecular targets for liver cancer therapy: From screening of target genes to clinical trials | |
| CN111944821A (zh) | 一种结肠癌核酸适体的组织样本快速筛选及其在检测制剂中的应用 | |
| AU2008357875A1 (en) | Interferon Epsilon (IFNE1) as a marker for targeted cancer therapy |